Abstracts tagged "monocytes and rheumatoid arthritis (RA)"

Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Ruth Fritsch-Stork¹, Sandra Cardoso¹, Jasper Broen¹, Marian Groot-Koerkamp², Arno Concepcion¹, Floris Lafeber¹ and Johannes W.J. Bijlsma¹, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Molecular Cancer Research, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…
Abstract Number: 881 • 2012 ACR/ARHP Annual Meeting
Microrna-155 Regulates Chemokines and Chemokine Receptors in Rheumatoid Arthritis Monocyte
Aziza Elmesmari¹, Derek S. Gilchrist¹, Alasdair R. Fraser¹, Diane Vaughan¹, Ross McQueenie², Gerard J. Graham¹, James Brewer³, Iain B. McInnes¹ and Mariola Kurowska-Stolarska¹, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Immunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is characterized by synovial tissue inflammation leading to joint destruction. Monocytes/macrophages are major effector cells in RA synovitis, principally by releasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].